Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease

Annals of Internal Medicine

Volumn 164, Issue 3, 2016, Pages 155-163

  Christensen, Kurt D ^a   Roberts, J Scott ^b   Whitehouse, Peter J ^c   Royal, Charmaine D M ^d   Obisesan, Thomas O ^e   Cupples, L Adrienne ^f   Vernarelli, Jacqueline A ^g   Bhatt, Deepak L ^h   Linnenbringer, Erin ⁱ   Butson, Melissa B ^c   Fasaye, Grace Ann ^j   Uhlmann, Wendy R ^k   Hiraki, Susan ^l   Wang, Na ^f   Cook Deegan, Robert ^d   Green, Robert C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d DUKE UNIVERSITY   (United States)

^e HOWARD UNIVERSITY HOSPITAL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g FAIRFIELD UNIVERSITY   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j WALTER REED ARMY MEDICAL CENTER   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l GENEDX   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; ALLELE; ALZHEIMER DISEASE; ANXIETY ASSESSMENT; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BEHAVIOR CHANGE; CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DISTRESS SYNDROME; FEMALE; FIRST DEGREE RELATIVE; GENETIC RISK; GENOTYPE; HEALTH BEHAVIOR; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PRIORITY JOURNAL; AGED; ANXIETY; GENETIC PREDISPOSITION; GENETICS; MENTAL STRESS; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANXIETY; APOLIPOPROTEIN E4; CORONARY ARTERY DISEASE; DEPRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84957641233     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0187     Document Type: Article

References (44)

1. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312: 1870-9. [PMID: 25326635] doi: 10.1001/jama .2014.14601
2. Green RC, Rehm HL, Kohane IS. Clinical genome sequencing. In: Ginsburg GS, Willard HF, eds. Genomic and Personalized Medicine. 2nd ed. San Diego: Academic Pr; 2013: 102-22.
3. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;370: 2418-25. [PMID: 24941179] doi: 10.1056/NEJMra1312543
4. Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014;86: 21-8. [PMID: 24684508] doi: 10.1111/cge.12392
5. Korf BR. Integration of genomics into medical practice. Discov Med. 2013;16: 241-8. [PMID: 24229741]
6. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15: 565-74. [PMID: 23788249] doi: 10.1038/gim.2013.73
7. ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing [Letter]. Genet Med. 2015; 17: 68-9. [PMID: 25356965] doi: 10.1038/gim.2014.151
8. Burke W, Antommaria AH, Bennett R, Botkin J, Clayton EW, Henderson GE, et al. Recommendations for returning genomic incidental findings? We need to talk!. Genet Med. 2013;15: 854-9. [PMID: 23907645] doi: 10.1038/gim.2013.113
9. Green RC, Lupski JR, Biesecker LG. Reporting genomic sequencing results to ordering clinicians: incidental, but not exceptional. JAMA. 2013;310: 365-6. [PMID: 23917280] doi: 10.1001/jama.2013 .41703
10. McGuire AL, Joffe S, Koenig BA, Biesecker BB, McCullough LB, Blumenthal-Barby JS, et al. Point-counterpoint. Ethics and genomic incidental findings. Science. 2013;340: 1047-8. [PMID: 23686340] doi: 10.1126/science.1240156
11. Weiner C. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and directto- consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol. 2014;180: 562-4. [PMID: 25150271] doi: 10.1093/aje/kwu217
12. Janssens AC. The hidden harm behind the return of results from personal genome services: a need for rigorous and responsible evaluation. Genet Med. 2015;17: 621-2. [PMID: 25412399] doi: 10.1038/gim.2014.169
13. Yu JH, Harrell TM, Jamal SM, Tabor HK, Bamshad MJ. Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. Am J Hum Genet. 2014;95: 77-84. [PMID: 24975944] doi: 10.1016/j.ajhg.2014.06.004
14. Wolf SM, Annas GJ, Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science. 2013;340: 1049-50. [PMID: 23686341] doi: 10.1126/science.1239119
15. Jackson L, Goldsmith L, O'Connor A, Skirton H. Incidental findings in genetic research and clinical diagnostic tests: a systematic review. Am J Med Genet A. 2012;158A: 3159-67. [PMID: 23166054] doi: 10.1002/ajmg.a.35615
16. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, et al. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet. 2011;89: 607-18. [PMID: 22077970] doi: 10.1016/j.ajhg.2011.10.004
17. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J. 2008;8: 85-9. [PMID: 17486108]
18. Kocarnik JM, Fullerton SM. Returning pleiotropic results from genetic testing to patients and research participants. JAMA. 2014; 311: 795-6. [PMID: 24481117] doi: 10.1001/jama.2014.369
19. Wachbroit R. The question not asked: the challenge of pleiotropic genetic tests. Kennedy Inst Ethics J. 1998;8: 131-44. [PMID: 11657425]
20. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE∗ 4 a 'thrifty' allele? Ann Hum Genet. 1999;63: 301-10. [PMID: 10738542]
21. Morris JC. Dementia update 2005. Alzheimer Dis Assoc Disord. 2005;19: 100-17. [PMID: 15942329]
22. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004; 141: 137-47. [PMID: 15262670] doi: 10.7326/0003-4819-141-2 -200407200-00013
23. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298: 1300-11. [PMID: 17878422]
24. Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, et al; REVEAL Study Group. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement. 2015;11: 1222-30. [PMID: 25499536] doi: 10.1016/j.jalz.2014.10.014
25. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et al; REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361: 245-54. [PMID: 19605829] doi: 10.1056/NEJMoa0809578
26. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008; 22: 94-7. [PMID: 18317253] doi: 10.1097/WAD.0b013e31815a9dcc
27. Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr. 2010;91: 1402-7. [PMID: 20219963] doi: 10.3945/ajcn.2009.28981
28. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005; 18: 250-5. [PMID: 16306249]
29. Roberts JS, Chen CA, Uhlmann WR, Green RC. Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med. 2012;14: 742-8. [PMID: 22498844] doi: 10.1038/gim.2012.37
30. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004;6: 192-6. [PMID: 15266206]
31. Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, et al. Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med. 2008;10: 207-14. [PMID: 18344711] doi: 10.1097/GIM .0b013e318164e4cf
32. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48: 314-8. [PMID: 3611032]
33. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56: 893-7. [PMID: 3204199]
34. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1: 385-401.
35. Santor DA, Zuroff DC, Ramsay JO, Cervantes P, Palacios J. Examining scale discriminability in the BDI and CES-D as a function of depressive severity. Psychol Assess. 1995;7: 131-9.
36. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41: 209-18. [PMID: 472086]
37. Payne K, Nicholls S, McAllister M, Macleod R, Donnai D, Davies LM. Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health. 2008;11: 497-508. [PMID: 18489673] doi: 10.1111/j.1524-4733.2007.00259.x
38. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid Assessment of Physical Activity (RAPA) among older adults. Prev Chronic Dis. 2006;3: A118. [PMID: 16978493]
39. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23: 1921-86. [PMID: 15195324]
40. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996;313: 36-9. [PMID: 8664772]
41. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26: 192-6. [PMID: 20857339] doi: 10.1007/s11606-010-1513-8
42. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10: 19-32. [PMID: 18197053] doi: 10.1097/GIM.0b013e31815f524f
43. Orne MT. On the social psychology of the psychological experiment: with particular reference to demand characteristics and their implications. Am Psychol. 1962;17: 776-83.
44. Online Mendelian Inheritance in Man. Apolipoprotein E; APOE. MIM number 107741. Baltimore: Johns Hopkins University; 2015. Accessed at www.omim.org/entry/107741 on 7 April 2015.